Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity by Ding, Yanning et al.
This is an author produced version of Epidermal growth factor upregulates motility of 
Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/78724/
Article:
Ding, Yanning, Brackenbury, William J. orcid.org/0000-0001-6882-3351, Onganer, Pinar U.
et al. (4 more authors) (2008) Epidermal growth factor upregulates motility of Mat-LyLu rat 
prostate cancer cells partially via voltage-gated Na+ channel activity. Journal of cellular 
physiology. pp. 77-81. ISSN 0021-9541 
https://doi.org/10.1002/jcp.21289
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
This is the pre-print version of the following article: Ding et al. (2008) J 
Cell Physiol 215 (1):77-81, which has been published in final form at 
http://onlinelibrary.wiley.com/doi/10.1002/jcp.21289/abstract. 
Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer 
cells via voltage-gated Na
+
 channel activity 
 
Yanning Ding
1,2
, William J. Brackenbury
1
, Pinar U. Onganer
1,3
, Ximena Montano
1,4
, 
Louise M. Porter
5
, Lucy F. Bates
1,6
 and Mustafa B. A. Djamgoz
1*
 
 
Present addresses: 
1 
Neuroscience Solutions to Cancer Research Group, 
4
 Molecular Signalling Group, 
Division of Cell and Molecular Biology, Sir Alexander Fleming Building, Imperial 
College London, South Kensington Campus, London SW7 2AZ, U.K. 
2 
Institute of Cancer Research, Cell and Molecular Biology, 237 Fulham Road, 
London SW3 6JB, U.K.  
3 
Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial 
College London, Hammersmith Hospital, London W12 0NN, U.K. 
5
 Coombe Girls School, Clarence Avenue, New Malden, Surrey KT3 3TU, U. K. 
6 
Biomedical Research Centre, University of Dundee, Ninewells Hospital and Medical 
School, Dundee, DD1 5SY, U.K.  
*Correspondence to:  
Prof M B A Djamgoz  
Tel: +44 207 594 5370  
Fax: +44 207 584 2056 
E-mail: m.djamgoz@imperial.ac.uk 
Running title: EGF regulation of sodium channel in prostate cancer 
Keywords: Voltage-gated sodium channel; prostate cancer; metastasis; Mat-LyLu 
cells; epidermal growth factor; nerve growth factor; migration. 
 2 
ABSTRACT 
 
The main aim of this investigation was to determine whether a functional relationship 
existed between epidermal growth factor (EGF) and voltage-gated sodium channel 
(VGSC) upregulation, both associated with strongly metastatic prostate cancer cells. 
Incubation with EGF for 24 h more than doubled VGSC current density. Similar 
treatment with EGF significantly and dose-dependently enhanced the cells' migration 
through Transwell filters. Both the patch clamp recordings and the migration assay 
suggested that endogenous EGF played a similar role. Importantly, co-application of 
EGF and tetrodotoxin, a highly selective VGSC blocker, abolished 65% of the 
potentiating effect of EGF. It is suggested that a significant portion of the EGF-
induced enhancement of migration occurred via VGSC activity. 
 
ABBREVIATIONS 
 
I-V, current-voltage; EGF, epidermal growth factor; EGFR, epidermal growth factor 
receptor; FBS, foetal bovine serum; MiI, migration index; NGF, nerve growth factor; 
PCa, prostate cancer; SEM, standard error; TTX, tetrodotoxin; VGSC, voltage-gated 
Na
+
 channel. 
 
INTRODUCTION 
 
Ionic activity plays a significant role in intracellular homeostasis under both 
physiological and pathophysiological conditions. Abnormally high levels of voltage-
gated Na
+
 channels (VGSCs) have been detected in rat and human metastatic prostate 
cancer (PCa) in vitro and in vivo (Grimes et al., 1995; Laniado et al., 1997; Smith et 
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al., 1998; Bennett et al., 2004; Diss et al., 2005) and also occurs in human 
glioblastomas (Labrakakis et al., 1997), oligodendrogliomas (Patt et al., 1996), 
melanomas (Allen et al., 1997), lung cancer (Blandino et al., 1995; Onganer and 
Djamgoz, 2005), medullary thyroid carcinomas (Klugbauer et al., 1995), neoplastic 
mesothelia (Fulgenzi et al., 2006), cervical cancer (Diaz et al., 2007) and breast 
cancer (Roger et al., 2003; Fraser et al., 2005). As regards the functional 
consequences of these VGSCs, most work has been done on PCa and it has been 
shown that VGSC activity enhances a range of metastatic cellular behaviours, 
including directional motility (Djamgoz et al., 2001; Fraser et al., 2003) and 
invasiveness (Grimes et al., 1995; Laniado et al., 1997). However, the mechanism(s) 
responsible for the VGSC upregulation in PCa is not known. VGSC expression 
generally is well known to be dynamic (Diss et al., 2004). In PCa, VGSC plasticity 
has been demonstrated by the sensitivity to external serum concentration, although the 
serum factor(s) responsible was not determined (Ding and Djamgoz, 2004). VGSC 
regulation by growth factors has been shown for a variety cells, including 
pheochromocytoma PC12 cells (Toledo-Aral et al., 1995) and neurones (Blum et al., 
2002). The role of growth factors has also been emphasised in PCa, as regards both 
androgen sensitivity (Culig et al., 1996) and progression from invasive to metastatic 
carcinoma (Culig et al., 1994). We have shown previously that nerve growth factor 
(NGF) upregulated functional VGSC expression and transwell migration in Mat-LyLu 
rat PCa cells but the two effects were not connected (Brackenbury and Djamgoz, 
2007). 
 
In the present study, we aimed to evaluate the role of epidermal growth factor (EGF) 
in this regard. EGF has recently been shown to potentiate VGSC currents in guinea 
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pig ventricular myocytes via tyrosine phosphorylation (Liu et al., 2007). Expressed 
prostatic fluid contains the highest concentration of EGF in the body (175.5 ng/ml; 
Russell et al., 1998; Gann et al., 1999), and EGF has been demonstrated to enhance 
cellular invasiveness, thus suggesting that it could also play a role in metastatic PCa 
(Turner et al., 1996; Kim et al., 1999; Montano and Djamgoz, 2004). These data 
collectively would suggest that EGF could underlie the VGSC upregulation in PCa. In 
the present study, we tested this hypothesis, again, using the Mat-LyLu rat Dunning 
cell model of PCa. These cells induce metastases in >90% of cases when injected into 
syngeneic rats (Isaacs et al., 1986) and express ∼1,800× more VGSC/Nav1.7 mRNA, 
compared with their weakly/non-metastatic counterparts (Diss et al., 2001), and 
generate functional VGSCs (Grimes et al., 1995). 
 
MATERIALS AND METHODS 
 
Cell culture 
Mat-LyLu cells were maintained in RPMI medium containing 1% heat-inactivated 
foetal bovine serum (FBS; Invitrogen/Gibco, Paisley, UK), supplemented with 250 
nM dexamethasone. Medium was supplemented with 2 mM glutamine, 1 mM sodium 
pyruvate, and 100 IU/ml penicillin/streptomycin (Invitrogen/Gibco) (Grimes et al., 
1995). 
 
Pharmacology 
Mat-LyLu cells were plated for 24 h, serum starved for another 24 h and then treated 
with pharmacological agent(s) for a further 24 h. The agents used, their working 
concentrations and suppliers were as follows: EGF, 100 ng/ml (Calbiochem, 
 5 
Nottingham, UK); AG1478, 1 µM (Calbiochem), an inhibitor of EGF receptor 
(EGFR) tyrosine kinase (e.g. Liu et al., 1999); tetrodotoxin (TTX), 500 nM 
(Alomone, Jerusalem, Israel); and EGFR antibody, 1 µg/ml (Oncogene Research 
Products/Calbiochem, Nottingham, UK). 
 
Electrophysiology 
Patch-clamp recordings were performed as detailed before (e.g. Grimes and Djamgoz, 
1998; Ding and Djamgoz, 2004). Patch pipettes were pulled from borosilicate glass 
capillaries (Clarke Electromedical GC100F) and typically had resistances of 5Ð10 
MΩ when filled with intracellular solution containing: 145 mM CsCl; 5 mM NaCl; 2 
mM MgCl2; 1 mM CaCl2; 11 mM EGTA and 10 mM HEPES (pH 7.2 adjusted with 1 
M CsOH). The extracellular solution contained 144 mM NaCl; 5.4 mM KCl; 1 mM 
MgCl2; 5 mM CaCl2; 5 mM HEPES and 5.6 mM glucose (pH 7.2 adjusted with 1 M 
NaOH). VGSC currents were recorded by pulsing membrane potentials from −50 to 
+70 mV in 10 mV increments, from a holding potential of −100 mV. 
 
Migration assay 
Details of this were described before (Fraser et al., 2005). Briefly, cells were seeded 
in multi-well dishes in tissue culture medium. Following drug treatment, cells were 
re-suspended using trypsin-EDTA and put onto 12 µm-pore Transwell filters 
(Corning, MA) at a density of 2 × 10
5
 cells/well. Following 6 h incubation, MTT 
assay was performed to determine the number of migrated cells. The optical density 
of the coloured reaction was measured at 570 nm on a plate reader. These 
measurements were plotted as a percentage of the fluorescence readings for migrated 
cells/original cell number plated in the upper chamber, giving migration index (MiI). 
 6 
In the text, MiI values given were normalized with respect to the control value 
(corresponding to untreated cells in 0% FBS) as 100%. 
 
Data analysis 
All data were analysed as means ± standard errors (SEM). For statistical comparisons, 
Student's t-test or ANOVA with NewmanÐKeuls post hoc analysis were used, as 
appropriate (Brackenbury and Djamgoz, 2006). 
 
RESULTS 
 
Initial observations suggested that Mat-LyLu cells grown in 0% FBS were viable for 
at least 24 h, the monolayer appearing flat and most cells having extended 
pseudopodia (Ding and Djamgoz, 2004). Treatment with EGF (100 ng/ml) for 24 h 
presented a more rounded and refractive form. 
 
EGF increased VGSC current amplitude 
Whole-cell patch clamp recordings showed that treatment of cells with EGF for 24 h 
increased the VGSC current amplitude (Fig. 1). Similar treatment for only 5 min had 
no effect. The effect of EGF was blocked completely by co-incubation with AG1478, 
an inhibitor of EGFR tyrosine kinase (Fig. 1). The currentÐvoltage (IÐV) relationships 
showed that activation voltages and voltages for peak were similar, around −40 and 
−10 mV, respectively, under all three conditions tested: 0% FBS, EGF- and AG1478-
treated (Fig. 1B). However, the mean peak current density of cells grown in the 
presence of EGF (68.1 ± 4.7 pA/pF; n = 19) was significantly (two- to sevenfold) 
greater than in 0% FBS (31.3 ± 2.8 pA/pF; n = 18; P < 0.01), anti-EGFR antibody 
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(9.4 ± 2.3 pA/pF; n = 5; P < 0.001) or EGF + AG1478 (20.6 ± 2.2 pA/pF; n = 9; 
P < 0.001; Fig. 1C). Thus, EGF upregulated VGSC functional expression and this was 
dependent on tyrosine kinase activity. Importantly, EGF + AG1478, or application of 
the anti-EGFR antibody by itself, reduced the VGSC current amplitude to levels 
significantly less than the control (Fig. 1A,C). The latter effects were consistent with 
biochemical data (not shown) in suggesting that some basal EGFR activity occurred. 
 
EGF enhanced cellular migration via VGSC activity 
Pre-treatment with 100 ng/ml EGF for 24 h significantly increased Mat-LyLu cell 
migration by 26 ± 4% (n = 14; P < 0.001; Fig. 2). This effect was dose-dependent (Fig. 
2A). Interestingly, following treatment with AG1478 (alone or with EGF), migration 
was significantly less than in 0% FBS, the control value (P < 0.01 and P < 0.05, 
respectively). These results would indicate possible involvement of endogenous EGF 
in migration, also apparent from the electrophysiology. There was no difference in the 
values of MiI for AG1478 and EGF + AG1478 (86 ± 3% and 89 ± 3%, respectively; 
P = 0.28; n = 14; Fig. 2B). This suggested that AG1478 blocked completely the effect 
of exogenous (and endogenous) EGF. TTX (500 nM) applied by itself during the 
assay, suppressed migration by 18 ± 3% (P < 0.001; n = 14; Fig. 2B). Importantly, in 
the presence of TTX (500 nM), exogenous EGF (100 ng/ml) still caused an increase 
in migration but this was ∼65% less than the effect of EGF alone (P < 0.05; n = 14; 
Fig. 2B). This result suggested that a significant portion of EGF signalling operated 
upstream of the VGSC in the same pathway controlling migration. 
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DISCUSSION 
 
Whereas advanced PCa initially responds to androgen ablation therapy, most patients 
eventually develop androgen-independent cancer, which often leads to metastatic 
disease (Kreis, 1995). The transition of androgen-dependent to independent status 
could be associated with increased EGF signalling (Limonta et al., 1995; Sherwood 
and Lee, 1995). Indeed, it is well established that EGF promotes migration of PCa 
cells (Zolfaghari and Djakiew, 1996; Kim et al., 1999). Also, in primary corneal 
epithelial cells disoriented in an external direct-current electric field when grown in 
serum free medium, directional motility was restored by addition of EGF (Zhao et al., 
1999). Thus, EGF and VGSC activity could both contribute to directional movement 
(Djamgoz et al., 2001; Fraser et al., 2003). The present study is the first to provide 
evidence in support of a functional relationship between EGF signalling and VGSC 
activity in PCa cells. Thus, adding EGF to Mat-LyLu cells serum-starved for 24 h 
increased VGSC current density and this was strongly EGFR-mediated. These effects 
were seen at a concentration of EGF, ca. 100 ng/ml, very similar to that found in 
expressed prostatic fluid (Gann et al., 1999). The somewhat limited increase in 
migration caused by EGF application may have been caused by the presence of 
endogenously secreted EGF (Fig. 2B). In agreement with this, and consistent with the 
electrophysiology (Fig. 1A,B), AG1478 alone also slightly but significantly reduced 
migration. The effect of TTX was also less than previously reported value of 40Ð50% 
for Mat-LyLu cells (Grimes et al., 1995). A likely cause of this is the serum-free 
condition used, which could have limited the involvement of VGSC activity in 
migration. Nevertheless, co-application of TTX with EGF blocked >50% of the EGF-
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induced increase in migration, suggesting that the enhancing effect of EGF occurred 
significantly via VGSC activity. 
 
Upregulation of VGSC activity by EGF may be through a direct interaction with 
channel protein, for example tyrosine phosphorylation (Liu et al., 2007). It is also 
possible that the effect may be indirect and involve mechanisms in addition to VGSC. 
Indeed, EGF is likely to regulate a multiplicity of cellular components in metastatic 
PCa cells, which in turn may also influence migration. For example, EGF has been 
reported to cause system-wide changes in actin cytoskeleton extracellular matrix, Ca
2+
 
signalling, pH, and transcription factor expression (Schalkwijk et al., 1995; Citri and 
Yarden, 2006; Lopez-Perez and Salazar, 2006; Mimura et al., 2006; Neumann-Giesen 
et al., 2007). Further work is required to evaluate these possibilities and to determine 
the signal transduction pathway involved in the EGF-induced VGSC upregulation. 
There are two other issues worthy of discussion. 
 
First, although both NGF and EGF upregulated VGSC expression, their effects upon 
migration were different, the EGF-induced effect involved VGSC activity (this study), 
the NGF effect did not (Brackenbury and Djamgoz, 2007). This is a clear 
demonstration of the growth factor multiplicity and diversity of metastatic cell 
behaviour control, in part involving upregulation of VGSC expression/activity. Such a 
situation could have consequences for treatment modes for metastatic disease 
(Onganer et al., 2005). 
 
Second, since (i) VGSC activity was shown earlier to control secretory membrane 
activity in PCa cells (Abdul and Hoosein, 2001; Mycielska et al., 2003; Krasowska et 
 10 
al., 2004) and (ii) PCa cells have been reported to secrete EGF (Connolly and Rose, 
1990, 1991; also inferred in the present study from the effects of AG1478), it is 
possible that there is a positive feed-back loop between VGSC activity/upregulation 
and EGF release (Montano and Djamgoz, 2004). Such a mechanism could have a 
significant accelerating effect upon metastatic PCa progression. 
 
Finally, EGF-induced upregulation of VGSC activity could also occur in other 
cancers, especially metastatic breast cancer which is known to be associated with both 
expression of EGF/EGFR (Atalay et al., 2003) and VGSC upregulation (Fraser et al., 
2005; Brackenbury et al., 2007). Hence, suppressing VGSC expression/activity, 
alongside the EGF system could have added therapeutic value in clinical management 
of metastatic disease. 
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LEGENDS TO FIGURES 
 
Figure 1 
Upregulation of VGSC activity in Mat-LyLu cells by treatment for 24 h with 
exogenous EGF. A: Typical VGSC current traces recorded from Mat-LyLu cells in 
different culture conditions: 0% FBS, EGF (100 ng/ml), EGF + AG1478 (1 µM), and 
anti-EGFR antibody (1 µg/ml). VGSC currents were recorded by pulsing membrane 
potentials from −50 to +70 mV in 10 mV increments, from a holding potential of 
−100 mV. B: Effects of EGF and EGF + AG1478 (as in A) on currentÐvoltage 
relationship. Peak values of VGSC current density were plotted against membrane 
potential, showing EGF-stimulated VGSC functional activity. C: Histograms showing 
mean values of peak VGSC current density recorded in different conditions (as in A). 
All data points shown are mean and SEM. Significance: *P < 0.05; **P < 0.01; 
***P < 0.001. 
 
Figure 2 
Effects of EGF, AG1478 and TTX on Transwell migration of Mat-LyLu cells. 
Migration index (MiI) values were expressed as percentages of the basal value in 0% 
FBS. A: DoseÐresponse relationship for the effect of EGF (1Ð100 ng/ml) on 
percentage increase in MiI (ΔMiI). B: Effects of EGF (100 ng/ml), AG1478 (1 µM) 
and TTX (500 nM), and their specific combinations on MiI. Data are shown relative 
to the control value for 0% FBS (100%). Bars represent means and SEMs (n = 14). 
These data were consistent with the following: (1) Both EGF/EGFR and VGSC 
activity were involved in potentiating Mat-LyLu cell migration. (2) The EGF-
stimulated enhancement of motility occurred partially via VGSC activity. 
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